Predicting the next round of drugs for Medicare price negotiation

Matthew Vogel; Adam Tellier; Rena M Conti

doi:10.1126/scitranslmed.adq5711

Predicting the next round of drugs for Medicare price negotiation

Sci Transl Med. 2024 Dec 4;16(776):eadq5711. doi: 10.1126/scitranslmed.adq5711. Epub 2024 Dec 4.

Authors

Matthew Vogel¹, Adam Tellier², Rena M Conti²

Affiliations

¹ John F. Kennedy School of Government, Harvard University, Cambridge, MA, USA.
² Questrom School of Business, Boston University, Boston, MA, USA.

PMID: 39630882
DOI: 10.1126/scitranslmed.adq5711

Abstract

There is uncertainty regarding which brand-name prescription drugs will have their prices negotiated by Medicare in 2025. This Viewpoint analyzes the process that will be used to select the next 15 drugs for price negotiation.

MeSH terms

Drug Costs*
Humans
Medicare* / economics
Negotiating*
Prescription Drugs / economics
United States

Substances

Prescription Drugs